ReShape Lifesciences Inc. (NASDAQ:RSLS) Short Interest Update

ReShape Lifesciences Inc. (NASDAQ:RSLSGet Free Report) was the recipient of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 2,170,000 shares, a growth of 598.6% from the May 15th total of 310,600 shares. Approximately 10.4% of the shares of the stock are short sold. Based on an average trading volume of 5,210,000 shares, the short-interest ratio is currently 0.4 days.

Institutional Investors Weigh In On ReShape Lifesciences

An institutional investor recently bought a new position in ReShape Lifesciences stock. Armistice Capital LLC acquired a new stake in shares of ReShape Lifesciences Inc. (NASDAQ:RSLSFree Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 188,000 shares of the medical device company’s stock, valued at approximately $64,000. Armistice Capital LLC owned approximately 5.45% of ReShape Lifesciences as of its most recent SEC filing. 22.06% of the stock is owned by institutional investors.

ReShape Lifesciences Price Performance

Shares of ReShape Lifesciences stock traded down $0.01 on Thursday, hitting $0.20. The company’s stock had a trading volume of 753,048 shares, compared to its average volume of 3,389,590. ReShape Lifesciences has a 1 year low of $0.14 and a 1 year high of $2.45. The firm has a fifty day moving average price of $0.19 and a 200-day moving average price of $0.21.

ReShape Lifesciences (NASDAQ:RSLSGet Free Report) last issued its quarterly earnings data on Wednesday, May 15th. The medical device company reported ($0.09) EPS for the quarter. The business had revenue of $1.94 million during the quarter. ReShape Lifesciences had a negative net margin of 130.99% and a negative return on equity of 207.78%.

ReShape Lifesciences Company Profile

(Get Free Report)

ReShape Lifesciences Inc provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus.

Further Reading

Receive News & Ratings for ReShape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReShape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.